Literature DB >> 17086194

Klotho converts canonical FGF receptor into a specific receptor for FGF23.

Itaru Urakawa1, Yuji Yamazaki, Takashi Shimada, Kousuke Iijima, Hisashi Hasegawa, Katsuya Okawa, Toshiro Fujita, Seiji Fukumoto, Takeyoshi Yamashita.   

Abstract

FGF23 is a unique member of the fibroblast growth factor (FGF) family because it acts as a hormone that derives from bone and regulates kidney functions, whereas most other family members are thought to regulate various cell functions at a local level. The renotropic activity of circulating FGF23 indicates the possible presence of an FGF23-specific receptor in the kidney. Here we show that a previously undescribed receptor conversion by Klotho, a senescence-related molecule, generates the FGF23 receptor. Using a renal homogenate, we found that Klotho binds to FGF23. Forced expression of Klotho enabled the high-affinity binding of FGF23 to the cell surface and restored the ability of a renal cell line to respond to FGF23 treatment. Moreover, FGF23 incompetence was induced by injecting wild-type mice with an anti-Klotho monoclonal antibody. Thus, Klotho is essential for endogenous FGF23 function. Because Klotho alone seemed to be incapable of intracellular signalling, we searched for other components of the FGF23 receptor and found FGFR1(IIIc), which was directly converted by Klotho into the FGF23 receptor. Thus, the concerted action of Klotho and FGFR1(IIIc) reconstitutes the FGF23 receptor. These findings provide insights into the diversity and specificity of interactions between FGF and FGF receptors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17086194     DOI: 10.1038/nature05315

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  712 in total

Review 1.  Biology of Fibroblast Growth Factor 23: From Physiology to Pathology.

Authors:  Marie Courbebaisse; Beate Lanske
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

2.  Therapeutic potential of klotho-FGF23 fusion polypeptides: WO2009095372.

Authors:  Mohammed S Razzaque
Journal:  Expert Opin Ther Pat       Date:  2010-07       Impact factor: 6.674

Review 3.  Hereditary disorders of renal phosphate wasting.

Authors:  Amir S Alizadeh Naderi; Robert F Reilly
Journal:  Nat Rev Nephrol       Date:  2010-10-05       Impact factor: 28.314

Review 4.  The expanding family of hypophosphatemic syndromes.

Authors:  Thomas O Carpenter
Journal:  J Bone Miner Metab       Date:  2011-12-14       Impact factor: 2.626

5.  Salt causes aging-associated hypertension via vascular Wnt5a under Klotho deficiency.

Authors:  Wakako Kawarazaki; Risuke Mizuno; Mitsuhiro Nishimoto; Nobuhiro Ayuzawa; Daigoro Hirohama; Kohei Ueda; Fumiko Kawakami-Mori; Shigeyoshi Oba; Takeshi Marumo; Toshiro Fujita
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

6.  Sustained Klotho delivery reduces serum phosphate in a model of diabetic nephropathy.

Authors:  Julia M Hum; Linda M O'Bryan; Arun K Tatiparthi; Erica L Clinkenbeard; Pu Ni; Martin S Cramer; Manoj Bhaskaran; Robert L Johnson; Jonathan M Wilson; Rosamund C Smith; Kenneth E White
Journal:  J Appl Physiol (1985)       Date:  2019-01-03

7.  Mineralizing enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in hyp mice.

Authors:  Andrew C Karaplis; Xiuying Bai; Jean-Pierre Falet; Carolyn M Macica
Journal:  Endocrinology       Date:  2012-10-04       Impact factor: 4.736

8.  Klotho protects against mouse renal fibrosis by inhibiting Wnt signaling.

Authors:  Minoru Satoh; Hajime Nagasu; Yoshitaka Morita; Terry P Yamaguchi; Yashpal S Kanwar; Naoki Kashihara
Journal:  Am J Physiol Renal Physiol       Date:  2012-10-03

Review 9.  Klotho and aging.

Authors:  Makoto Kuro-o
Journal:  Biochim Biophys Acta       Date:  2009-02-20

10.  Subtle Difference Generates Big Dissimilarity: Comparison of Enzymatic Activity in KL1 and KL2 Domains of Lancelet Klotho.

Authors:  Zengyu Ma; Baozhen Qu; Shenjie Zhong; Lan Yao; Zhan Gao; Shicui Zhang
Journal:  Mar Biotechnol (NY)       Date:  2019-05-03       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.